National Cancer Center, Korea
ncc.re.krTotal trials
200
Active
36
Phase 3
24
Total enrollment
77,513
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 16 of 16 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Cisplatin | — | — | — | — | 6 | ||
| 7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin | — | — | — | — | — | 1 | |
| LAC triple therapy | — | — | — | — | — | 1 | |
| 10-day bismuth-based quadruple therapy | — | — | — | — | — | 1 | |
| Aspirin 100mg | — | — | — | — | — | 1 | |
| Gemcitabine | — | — | — | — | — | 6 | |
| Capecitabine | — | — | — | — | — | 3 | |
| Atezolizumab | — | — | — | — | — | 2 | |
| Pembrolizumab / Lenvatinib | — | — | — | — | — | 1 | |
| Lurbinectedin 4 MG Injection [Zepzelca] | — | — | — | — | — | 1 | |
| Lenvatinib | — | — | — | — | — | 1 | |
| Mitomycin-C | — | — | — | — | — | 1 | |
| Tripegfilgrastim | — | — | — | — | — | 1 | |
| Lazertinib | — | — | — | — | — | 1 | |
| Bevacizumab Injectable Product | — | — | — | — | — | 1 | |
| Levothyroxin | — | — | — | — | — | 1 |
Next readouts
- 2016-06
- 2018-12
- 2026-06-30
- 2026-09-05
- 2026-12-31
- 2027-02-28
- 2027-03-01
- 2027-12-31
- 2027-12-31
- 2027-12-31
Top conditions
- Breast Cancer20
- Gastric Cancer16
- Lung Cancer13
- Pancreatic Cancer11
- Early Gastric Cancer10
- Rectal Cancer7
- Metastatic Breast Cancer6
- Stomach Neoplasms5
Frequently asked questions about National Cancer Center, Korea
- How many clinical trials does National Cancer Center, Korea have on ClinicalTrials.gov?
- National Cancer Center, Korea is listed as the lead sponsor on 200 clinical trials in ClinicalTrials.gov, 36 of which are currently active (recruiting, enrolling, or ongoing).
- How many of National Cancer Center, Korea's trials are in Phase 3?
- 24 of National Cancer Center, Korea's trials are in Phase 3, spread across 16 active drug programs.
- What therapeutic areas does National Cancer Center, Korea focus on?
- National Cancer Center, Korea's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Gastric Cancer, Lung Cancer, Pancreatic Cancer, Early Gastric Cancer.
- When are National Cancer Center, Korea's next clinical trial readouts?
- National Cancer Center, Korea has 10 upcoming primary-completion readouts tracked here; the soonest is “Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD”, expected around 2016-06.